Leveraging Mycobacterium tuberculosis Rv1507A Protein for Improved Immunogenicity in Mycobacterium bovis BCG Vaccine
Immunology · 2026
DOI: 10.1111/imm.70063 ↗Kurz gefasst
Fachartikel in der Zeitschrift Immunology, 2026. Verfasst von Nilofer Naqvi und 6 weiteren Autor:innen. Beteiligte Einrichtung: Cell Signaling and Inflammation Biology Lab, ICMR-National Institute of Pathology, New Delhi, India. Hauptthemen laut MEDLINE: BCG Vaccine, Mycobacterium tuberculosis, Bacterial Proteins, Antigens, Bacterial. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 74 Literaturangaben. Gefördert von: Science and Engineering Research Board, Ministry of Health.
Abstract (Originalsprache)
Tuberculosis (TB) remains a global health burden, particularly because of the limited efficacy of the Bacillus Calmette‐Guérin (BCG) vaccine against adult pulmonary TB. To improve immunogenicity, we developed a recombinant BCG strain expressing the M. tuberculosis ‐specific antigen Rv1507A (rBCG_Rv1507A) and evaluated its immune‐enhancing potential. rBCG_Rv1507A‐infected human PBMCs and murine macrophages exhibited enhanced co‐stimulatory marker expression and Th1‐skewed cytokine profiles in vitro. The vaccine stimulated the expansion of T follicular helper (TFH) cells and both central and effector memory T cells. Intratracheal immunisation induced systemic and mucosal antibody responses, localized memory B cell formation, and enrichment of lung‐resident memory T cells in vivo. Importantly, rBCG_Rv1507A promoted macrophage apoptosis and suppressed autophagy, which may support cross‐antigen presentation. Furthermore, it induces features of trained immunity, including hematopoietic progenitor expansion and metabolic reprogramming of macrophages. These immunological enhancements were compartmentalized to the lungs, the primary site of TB infection, due to mucosal delivery. Collectively, rBCG_Rv1507A demonstrated potential as a next‐generation TB vaccine by integrating durable adaptive memory with innate immune training. However, further studies are required to confirm its protective efficacy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Cell Signaling and Inflammation Biology Lab, ICMR-National Institute of Pathology, New Delhi, India.
- Department of Life Science, School of Basic Sciences and Research, Sharda University, Greater Noida, India.
- GITAM School of Science, GITAM University, Hyderabad, India.
- Department of Transplant Immunology and Immunogenetics, All India Institute of Medical Sciences, New Delhi, India.
- Department of Biochemical Engineering and Biotechnology, Indian Institute of Technology, New Delhi, India.
ORCID-Profile: Seyed E Hasnain
Förderung
- Science and Engineering Research Board
- Ministry of Health
Zitieren
APA
Naqvi, N., Alam, A., Shariq, M., Ahuja, Y., Mitra, D. K., Hasnain, S. E., & Ehtesham, N. Z. (2026). Leveraging Mycobacterium tuberculosis Rv1507A Protein for Improved Immunogenicity in Mycobacterium bovis BCG Vaccine. Immunology. https://doi.org/10.1111/imm.70063
Vancouver
Naqvi N, Alam A, Shariq M, Ahuja Y, Mitra DK, Hasnain SE, et al. Leveraging Mycobacterium tuberculosis Rv1507A Protein for Improved Immunogenicity in Mycobacterium bovis BCG Vaccine. Immunology. 2026. doi:10.1111/imm.70063
BibTeX
@article{Naqvi2026,
author = {Naqvi, Nilofer and Alam, Anwar and Shariq, Mohd and Ahuja, Yashika and Mitra, Dipendra K and Hasnain, Seyed E and Ehtesham, Nasreen Z},
title = {Leveraging Mycobacterium tuberculosis Rv1507A Protein for Improved Immunogenicity in Mycobacterium bovis BCG Vaccine},
journal = {Immunology},
year = {2026},
doi = {10.1111/imm.70063}
}
EUVIMED